Biomarker-Based Risk Stratification Tool in Pediatric Acute Respiratory Distress Syndrome: Single-Center, Longitudinal Validation in a 2014-2019 Cohort

Overview

Journal Pediatr Crit Care Med

Specialty Pediatrics

Date 2024 Apr 9

PMID 38591949

Authors

Jane E Whitney

Grace M Johnson

Brian M Varisco

Benjamin A Raby

Nadir Yehya

Affiliations

Soon will be listed here.

Abstract

Objectives: The Pediatric Acute Respiratory Distress Syndrome Biomarker Risk Model (PARDSEVERE) used age and three plasma biomarkers measured within 24 hours of pediatric acute respiratory distress syndrome (ARDS) onset to predict mortality in a pilot cohort of 152 patients. However, longitudinal performance of PARDSEVERE has not been evaluated, and it is unclear whether the risk model can be used to prognosticate after day 0. We, therefore, sought to determine the test characteristics of PARDSEVERE model and population over the first 7 days after ARDS onset.

Design: Secondary unplanned post hoc analysis of data from a prospective observational cohort study carried out 2014-2019.

Setting: University-affiliated PICU.

Patients: Mechanically ventilated children with ARDS.

Interventions: None.

Measurements And Main Results: Between July 2014 and December 2019, 279 patients with ARDS had plasma collected at day 0, 266 at day 3 (11 nonsurvivors, two discharged between days 0 and 3), and 207 at day 7 (27 nonsurvivors, 45 discharged between days 3 and 7). The actual prevalence of mortality on days 0, 3, and 7, was 23% (64/279), 14% (38/266), and 13% (27/207), respectively. The PARDSEVERE risk model for mortality on days 0, 3, and 7 had area under the receiver operating characteristic curve (AUROC [95% CI]) of 0.76 (0.69-0.82), 0.68 (0.60-0.76), and 0.74 (0.65-0.83), respectively. The AUROC data translate into prevalence thresholds for the PARDSEVERE model for mortality (i.e., using the sensitivity and specificity values) of 37%, 27%, and 24% on days 0, 3, and 7, respectively. Negative predictive value (NPV) was high throughout (0.87-0.90 for all three-time points).

Conclusions: In this exploratory analysis of the PARDSEVERE model of mortality risk prediction in a population longitudinal series of data from days 0, 3, and 7 after ARDS diagnosis, the diagnostic performance is in the "acceptable" category. NPV was good. A major limitation is that actual mortality is far below the prevalence threshold for such testing. The model may, therefore, be more useful in cohorts with higher mortality rates (e.g., immunocompromised, other countries), and future enhancements to the model should be explored.

References

Gertz S, Bhalla A, Chima R, Emeriaud G, Fitzgerald J, Hsing D . Immunocompromised-Associated Pediatric Acute Respiratory Distress Syndrome: Experience From the 2016/2017 Pediatric Acute Respiratory Distress Syndrome Incidence and Epidemiology Prospective Cohort Study. Pediatr Crit Care Med. 2024; 25(4):288-300. PMC: 10994753. DOI: 10.1097/PCC.0000000000003421. View

Prasertsan P, Anantasit N, Walanchapruk S, Roekworachai K, Samransamruajkit R, Vaewpanich J . Sepsis-related pediatric acute respiratory distress syndrome: A multicenter prospective cohort study. Turk J Emerg Med. 2023; 23(2):96-103. PMC: 10166285. DOI: 10.4103/tjem.tjem_237_22. View

Viele K, Girard T . Risk, Results, and Costs: Optimizing Clinical Trial Efficiency through Prognostic Enrichment. Am J Respir Crit Care Med. 2020; 203(6):671-672. PMC: 7958522. DOI: 10.1164/rccm.202009-3649ED. View

Valentine S, Kudchadkar S, Ward S, Morrow B, Nadkarni V, Curley M . Nonpulmonary Treatments for Pediatric Acute Respiratory Distress Syndrome: From the Second Pediatric Acute Lung Injury Consensus Conference. Pediatr Crit Care Med. 2023; 24(12 Suppl 2):S45-S60. DOI: 10.1097/PCC.0000000000003158. View

Rowan C, Randolph A, Iyer N, Korang S, Kneyber M . Pulmonary Specific Ancillary Treatment for Pediatric Acute Respiratory Distress Syndrome: From the Second Pediatric Acute Lung Injury Consensus Conference. Pediatr Crit Care Med. 2023; 24(12 Suppl 2):S99-S111. DOI: 10.1097/PCC.0000000000003162. View

Yehya N, Topjian A, Thomas N, Friess S . Improved oxygenation 24 hours after transition to airway pressure release ventilation or high-frequency oscillatory ventilation accurately discriminates survival in immunocompromised pediatric patients with acute respiratory distress syndrome*. Pediatr Crit Care Med. 2014; 15(4):e147-56. PMC: 4114308. DOI: 10.1097/PCC.0000000000000069. View

Kneyber M, Cheifetz I, Curley M . High-frequency oscillatory ventilation for PARDS: awaiting PROSPect. Crit Care. 2020; 24(1):118. PMC: 7099805. DOI: 10.1186/s13054-020-2829-3. View

Seo J, Park J, Lee E, Thuy Lu Vo T, Choi H, Kim J . ARD1-mediated Hsp70 acetylation balances stress-induced protein refolding and degradation. Nat Commun. 2016; 7:12882. PMC: 5059642. DOI: 10.1038/ncomms12882. View

Yehya N, Smith L, Thomas N, Steffen K, Zimmerman J, Lee J . Definition, Incidence, and Epidemiology of Pediatric Acute Respiratory Distress Syndrome: From the Second Pediatric Acute Lung Injury Consensus Conference. Pediatr Crit Care Med. 2023; 24(12 Suppl 2):S87-S98. DOI: 10.1097/PCC.0000000000003161. View

10.

Sinha P, Meyer N, Calfee C . Biological Phenotyping in Sepsis and Acute Respiratory Distress Syndrome. Annu Rev Med. 2022; 74:457-471. PMC: 10617629. DOI: 10.1146/annurev-med-043021-014005. View

11.

Wong H, Salisbury S, Xiao Q, Cvijanovich N, Hall M, Allen G . The pediatric sepsis biomarker risk model. Crit Care. 2012; 16(5):R174. PMC: 3682273. DOI: 10.1186/cc11652. View

12.

Akobeng A . Understanding diagnostic tests 2: likelihood ratios, pre- and post-test probabilities and their use in clinical practice. Acta Paediatr. 2007; 96(4):487-91. DOI: 10.1111/j.1651-2227.2006.00179.x. View

13.

Bossuyt P, Reitsma J, Bruns D, Gatsonis C, Glasziou P, Irwig L . STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies. BMJ. 2015; 351:h5527. PMC: 4623764. DOI: 10.1136/bmj.h5527. View

14.

Wong H, Weiss S, Giuliano Jr J, Wainwright M, Cvijanovich N, Thomas N . Testing the prognostic accuracy of the updated pediatric sepsis biomarker risk model. PLoS One. 2014; 9(1):e86242. PMC: 3906040. DOI: 10.1371/journal.pone.0086242. View

15.

Balayla J . Prevalence threshold (ϕe) and the geometry of screening curves. PLoS One. 2020; 15(10):e0240215. PMC: 7540853. DOI: 10.1371/journal.pone.0240215. View

16.

Stanski N, Wong H . Prognostic and predictive enrichment in sepsis. Nat Rev Nephrol. 2019; 16(1):20-31. PMC: 7097452. DOI: 10.1038/s41581-019-0199-3. View

17.

Gaies M, Gurney J, Yen A, Napoli M, Gajarski R, Ohye R . Vasoactive-inotropic score as a predictor of morbidity and mortality in infants after cardiopulmonary bypass. Pediatr Crit Care Med. 2009; 11(2):234-8. DOI: 10.1097/PCC.0b013e3181b806fc. View

18.

Pollack M, Patel K, Ruttimann U . PRISM III: an updated Pediatric Risk of Mortality score. Crit Care Med. 1996; 24(5):743-52. DOI: 10.1097/00003246-199605000-00004. View

19.

Dowell J, Parvathaneni K, Thomas N, Khemani R, Yehya N . Epidemiology of Cause of Death in Pediatric Acute Respiratory Distress Syndrome. Crit Care Med. 2018; 46(11):1811-1819. PMC: 6185780. DOI: 10.1097/CCM.0000000000003371. View

20.

Whitney J, Zhang B, Koterba N, Chen F, Bush J, Graham K . Systemic Endothelial Activation Is Associated With Early Acute Respiratory Distress Syndrome in Children With Extrapulmonary Sepsis. Crit Care Med. 2020; 48(3):344-352. PMC: 8749338. DOI: 10.1097/CCM.0000000000004091. View